Current Status and Progress of Radioligand Therapy in Advanced Malignant Tumors Yazar: Dasheng QIU, NAGARAJAH James, Diansheng CUI, Shaozhong WEI

Konular: “…radioligand therapy…”
Tam Metin Erişim

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches Yazar: Zool Hilmi Awang, Markus Essler, Hojjat Ahmadzadehfar

Konular: Tam Metin Erişim

A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer Yazar: Andreas Tulipan, Clemens Kratochwil, Jacob Lilleby, Wolfgang Lilleby

Konular: Tam Metin Erişim

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT Yazar: Florian Rosar, Caroline Burgard, Scott David, Robert J. Marlowe, Mark Bartholomä, Stephan Maus, Sven Petto, Fadi Khreish, Andrea Schaefer-Schuler, Samer Ezziddin

Konular: Tam Metin Erişim

Advances in PSMA theranostics Yazar: Thomas M. Jeitner, John W. Babich, James M. Kelly

Konular: Tam Metin Erişim

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials Yazar: Alexander Konopnicki, Michael Zaliznyak, Mathews Roy, Bagi Jana

Konular: Tam Metin Erişim

Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies Yazar: Joseph Lau, Hwan Lee, Julie Rousseau, François Bénard, Kuo-Shyan Lin

Konular: “…radioligand therapy…”
Tam Metin Erişim

Establishing a robust radioligand therapy program: A practical approach for North American centers Yazar: Erik S. Mittra, Rebecca K. S. Wong, Celeste Winters, Adam Brown, Shondra Murley, Hagen Kennecke

Konular: Tam Metin Erişim

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies Yazar: Alexander Wurzer, Francesco De Rose, Sebastian Fischer, Markus Schwaiger, Wolfgang Weber, Stephan Nekolla, Hans-Jürgen Wester, Matthias Eiber, Calogero D’Alessandria

Konular: Tam Metin Erişim

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues Yazar: Seiji Hoshi, Kei Yaginuma, Satoru Meguro, Akifumi Onagi, Kanako Matsuoka, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Motohide Uemura, Yoshiyuki Kojima

Konular: Tam Metin Erişim

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy Yazar: Florian Rosar, Niklas Schön, Hendrik Bohnenberger, Mark Bartholomä, Tobias Stemler, Stephan Maus, Fadi Khreish, Samer Ezziddin, Andrea Schaefer-Schuler

Konular: Tam Metin Erişim

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors? Yazar: Veronika Barbara Felber, Manuel Amando Valentin, Hans-Jürgen Wester

Konular: Tam Metin Erişim

Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand? Yazar: Francesco Dondi, Alberto Miceli, Guido Rovera, Vanessa Feudo, Claudia Battisti, Maria Rondini, Andrea Marongiu, Antonio Mura, Riccardo Camedda, Maria Silvia De Feo, Miriam Conte, Joana Gorica, Cristina Ferrari, Anna Giulia Nappi, Giulia Santo

Konular: Tam Metin Erişim

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with ¹⁷⁷Lu-PSMA and Combined ²²⁵Ac- and ¹⁷⁷Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Ad... Yazar: Thomas Langbein, Harshad R. Kulkarni, Christiane Schuchardt, Dirk Mueller, Gerd Fabian Volk, Richard P. Baum

Konular: Tam Metin Erişim

Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy Yazar: Jonatan Dewulf, Sam Massa, Laurent Navarro, Yana Dekempeneer, Francis Santens, Hannelore Ceuppens, Karine Breckpot, Jo A. Van Ginderachter, Tony Lahoutte, Matthias D’Huyvetter, Nick Devoogdt

Konular: Tam Metin Erişim

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 Yazar: Catherine Meyer, Vikas Prasad, Andreea Stuparu, Peter Kletting, Gerhard Glatting, Jonathan Miksch, Christoph Solbach, Katharina Lueckerath, Lea Nyiranshuti, Shaojun Zhu, Johannes Czernin, Ambros J. Beer, Roger Slavik, Jeremie Calais, Magnus Dahlbom

Konular: Tam Metin Erişim

Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges Yazar: Suliman Salih, Ajnas Alkatheeri, Wijdan Alomaim, Aisyah Elliyanti

Konular: Tam Metin Erişim

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management Yazar: Sonia Mahajan, Ravinder K. Grewal, Kent P. Friedman, Heiko Schöder, Neeta Pandit-Taskar

Konular: Tam Metin Erişim

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort o... Yazar: Aaron R. Hansen, Stephan Probst, Jean-Mathieu Beauregard, Benjamin L. Viglianti, Jeff M. Michalski, Scott T. Tagawa, Oliver Sartor, Ronald F. Tutrone, Orhan K. Oz, Kevin D. Courtney, Ebrahim S. Delpassand, Luke T. Nordquist, Medhat M. Osman, Kim N. Chi, Richard Sparks, Noble George, Sara M. Hawley, Wenting Wu, Jessica D. Jensen, Neil E. Fleshner

Konular: Tam Metin Erişim

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT Yazar: Astrid Gosewisch, Harun Ilhan, Sebastian Tattenberg, Andrea Mairani, Katia Parodi, Julia Brosch, Lena Kaiser, Franz Josef Gildehaus, Andrei Todica, Sibylle Ziegler, Peter Bartenstein, Guido Böning

Konular: “…Radioligand therapy…”
Tam Metin Erişim